Ablynx Adds Sanofi To Its List Of Big Pharma Partners

Sanofi is the latest big pharma, following on from Merck & Co., AbbVie and others, to team up with Belgian Nanobody drug developer Ablynx.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light. — Sanofi & Ablynx Sign R&D Deal For Novel Therapies Targeting Immune Disorders • Source: Shutterstock

Sanofi is paying €23m upfront to Belgium-based Ablynx NV for access to the latter company's Nanobody-based therapeutic platform; the pair will develop novel treatments for various immune mediated inflammatory diseases.

Under the agreement, Ablynx will receive research funding of around €8m for preclinical development of the initially selected targets

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

12 May 2025

• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.